Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors

US10183036B2 · kind B2 · utility

Assignee

• ChromaDex Inc. · US

Inventors

• Ryan Dellinger · Azusa, US
• Troy Rhonemus · Plymouth, US
• Mark A. Morris · Somerville, US
• Aron Erickson · Longmont, US
• Hadi Casser · Northglenn, US
• Marie Eugenie Migaud · Lurgan, GB

Key dates

• Filing date: Apr 20, 2017
• Grant date: Jan 22, 2019
• Expiry date: Apr 20, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (“NAD+”) or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided.